3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
113
Colonic Neoplasms
30
Neoplasm Metastasis
28
Rectal Neoplasms
27
Neoplasms
27
Carcinoma, Non-Small-Cell Lung
14
Esophageal Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
9
Pancreatic Neoplasms
9
Head and Neck Neoplasms
9
Lung Neoplasms
8
Cholangiocarcinoma
7
Carcinoma, Squamous Cell
6
Breast Neoplasms
6
Colorectal Cancer Metastatic
5
Carcinoma
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Inflammatory Breast Neoplasms
3
Gastrointestinal Neoplasms
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Kidney Neoplasms
2
Glioma
2
Fallopian Tube Neoplasms
2
Interventions
Gemcitabine
60
Cisplatin
38
Oxaliplatin
30
Capecitabine
28
Fluorouracil
21
Leucovorin
19
pembrolizumab
11
Irinotecan
11
durvalumab
9
130-nm albumin-bound paclitaxel
9
Erlotinib Hydrochloride
8
Trastuzumab
7
Bevacizumab
7
Platinum
6
Magnetic Resonance Spectroscopy
6
Albumin-Bound Paclitaxel
6
1,2-diaminocyclohexaneplatinum II citrate
6
Taxes
5
Specimen Handling
5
Sorafenib
5
Radiotherapy
5
Carboplatin
5
Docetaxel
4
Biopsy
4
trifluridine tipiracil drug combination
3
dehydroftorafur
3
atezolizumab
3
Paclitaxel
3
Lapatinib
3
Interleukin-12 Subunit p35
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gallbladder Neoplasms
×
Panitumumab
×
Clear all
NCT01308840
2016-08-17
UGIH09067
University of Rochester
Phase 2
Completed
31 enrolled
10 charts